logo

Ascites Market, By Diagnosis (R-Ray, Physical Examination, Ultrasound and CT Scan), By Treatment (Chemotherapy, Diuretic, Paracentesis, Surgeries and Others) By End User (Hospital, ASC, Cardiology Center) opportunities and forecast 2020-2027

  • DLR2205
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Accumulation of the fluid in peritoneal cavity that is, the space between the lining of abdominal and abdomen organs, is denoted as ascites. Liver cirrhosis is the common case of ascites. Incidence of ascites is sign of important portal hypertension. The high pressure in the blood vessels of the liver and low levels of the albumin results in ascites. Moreover, less common aspects such as kidney failure, infection in pancreas, cancers and heart failure could contribute to ascites development.

Rise in the prevalence of liver cirrhosis is projected to drive the global market. Additionally, surge in number of the patients suffering from the liver cirrhosis due to rise in alcohol consumption is anticipated to drive global market. Rise in the cases of cancer and progress in reimbursement also boost growth of global market. Though, complications related with the disease treatment is one of factors expected to restrain global ascites market.

Segment Overview

The ascites market can be segmented on the basis of type, diagnosis, and treatment. Based on diagnosis, the market can be divided into ultrasound, angiography, CT scan, laparoscopy, and others.

The ultrasound segment is expected to grow at a fast pace over the forecast period. Based on the treatment, market can be categorised into paracentesis, medicinal therapy, liver transplantation, and others. Based on end-user, the global market can be segmented into clinics, hospitals, diagnostics centers, ambulatory surgical centers, and others.

Regional Overview

North America lead the global market in 2019 due to the developed technologies, high health care expenditure, rise in incidence of cirrhosis, and occurrence of leading players in region. Increasing awareness about the ascites diagnostic test and the related treatments is expected to drive market in Europe. Moreover, skilled health care specialists, increase in alcohol consumption, and the obesity are the major factors to expect to propel ascites market in region over the forecast period.

Moreover, rise in incidence of cirrhosis and increase in the number of surgeries are expected to augment the market in the region.
Asia Pacific is projected to be the fastest developing market for disease treatment owing to surge in awareness around ascites and associated treatment, fast developing health care arrangement, and increase in the literacy rate. Poor economy and the inadequate health care arrangement are likely to hamper growth of the market in Middle East & Africa.

Competitor overview

The global market is extremely fragmented due to presence of large number of local and global players. Focus on advanced treatment options is anticipated to drive global market over the forecast period. Major players operating in the market are PharmaCyte, Sofinnova, Sequana Medical NV, Biotech Inc., BioVie, Inc., Medtronic plc, Becton, Dickinson and Company, GI Supply, Fresenius SE & Co. KGaA, QED Bioscience, Inc., and Abcore, Inc.

Key Players
  1. Sofinnova,
  2. PharmaCyte, Biotech Inc.,
  3. Sequana Medical NV,
  4. BioVie, Inc., Becton,
  5. Dickinson and Company,
  6. Medtronic plc,
  7. GI Supply,
  8. QED Bioscience, Inc.,
  9. Fresenius SE & Co. KGaA,
  10. Abcore, Inc.

Market Segmentation

By Diagnosis
  • X-Ray Test,
  • Physical Examination,
  • Ultrasound
  • CT scans
By Treatment
  • Diuretics,
  • Chemotherapy,
  • Paracentesis
  • Surgeries
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 12

    2 Market Introduction 14

    • 2.1 Research Objective 14
    • 2.2 Assumptions & Limitations 14
      • 2.2.1 Assumptions 14
      • 2.2.2 Limitations 14
    • 2.3 Market Structure 15

    3 Market Dynamics 16

    • 3.1 Introduction 16
    • 3.2 Drivers 17
      • 3.2.1 Rising Prevalence of Cirrhosis (Impact Weightage: 35%) 17
      • 3.2.2 Improvement in Reimbursement Policies (Impact Weightage: 30%) 18
      • 3.2.3 Increasing Occurrence of Cancer (Impact Weightage: 35%) 19
    • 3.3 Restraints 20
      • 3.3.1 Complications associated with the ascites treatment 20
    • 3.4 Opportunity 21
      • 3.4.1 Development of Innovative Treatment Options 21
    • 3.5 Macroeconomic Indicators 21

    4 Market Factor Analysis 22

    • 4.1 Porter’s Five Forces Model 22
      • 4.1.1 Bargaining Power of Suppliers 23
      • 4.1.2 Bargaining Power of Buyers 23
      • 4.1.3 Threat of New Entrants 23
      • 4.1.4 Threat of Substitutes 23
      • 4.1.5 Intensity of Rivalry 23
    • 4.2 Value Chain Analysis: Global Ascites Market 24
      • 4.2.1 R&D and Designing 24
      • 4.2.2 Manufacturing 25
      • 4.2.3 Distribution & Sales 25
      • 4.2.4 Post-sales Monitoring 25
    • 4.3 Demand & Supply: Gap Analysis 26
    • 4.4 Pricing Analysis 26

    5 Global Ascites Market by Types 27

    • 5.1 Introduction 27
    • 5.2 Transudative Ascites 28
    • 5.3 Exudate Ascites 29

    6 Global Ascites Market by Diagnosis 30

    • 6.1 Introduction 30
    • 6.2 Ultrasound 31
    • 6.3 CT scan 32
    • 6.4 Laparoscopy 32
    • 6.5 Angiography 33

    7 Global Ascites Market by Treatment 34

    • 7.1 Introduction 34
    • 7.2 Surgeries 36

    8 Global Ascites Market by End Users 37

    • 8.1 Introduction 37
    • 8.2 Hospitals & Clinics 38
    • 8.3 Ambulatory Surgical Center 39
    • 8.4 Diagnostic Centres 39

    9 Global Ascites Market by Regions 40

    • 9.1 Introduction 40
    • 9.2 Americas 42
      • 9.2.1 North America 45
        • 9.2.1.1 US 47
        • 9.2.1.2 Canada 49
      • 9.2.2 South America 51
        • 9.2.2.1 Brazil 53
        • 9.2.2.2 Colombia 55
        • 9.2.2.3 Mexico 57
        • 9.2.2.4 Rest of South America 59
  • 9.3 Europe 61
    • 9.3.1 Western Europe 64
      • 9.3.1.1 Germany 66
      • 9.3.1.2 France 68
      • 9.3.1.3 UK 70
      • 9.3.1.4 Italy 72
      • 9.3.1.5 Spain 74
      • 9.3.1.6 Rest of Western Europe 76
    • 9.3.2 Eastern Europe 78
  • 9.4 Asia Pacific 80
    • 9.4.1 China 83
    • 9.4.2 Japan 85
    • 9.4.3 India 87
    • 9.4.4 Australia 89
    • 9.4.5 Republic of Korea 91
    • 9.4.6 Rest of Asia Pacific 93
  • 9.5 Middle East & Africa 95
    • 9.5.1 Middle East 98
      • 9.5.1.1 UAE 100
      • 9.5.1.2 Saudi Arabia 102
      • 9.5.1.3 Oman 104
      • 9.5.1.4 Kuwait 106
      • 9.5.1.5 Qatar 108
      • 9.5.1.6 Rest of Middle East 110
    • 9.5.2 Africa 112

    • 10 Competitive Analysis 114

    • 10.1 Sequana Medical 114
      • 10.1.1 Company Overview 114
      • 10.1.2 Financials 114
      • 10.1.3 Products 114
      • 10.1.4 Strategy 114
      • 10.1.5 Key Developments 114
    • 10.2 BioVie 115
      • 10.2.1 Company Overview 115
      • 10.2.2 Financials 115
      • 10.2.3 Products 115
      • 10.2.4 Strategy 115
      • 10.2.5 Key Developments 115
    • 10.3 PharmaCyte Biotech Inc. 116
      • 10.3.1 Company Overview 116
      • 10.3.2 Financials 116
      • 10.3.3 Products 116
      • 10.3.4 Strategy 116
      • 10.3.5 Key Developments 116
    • 10.4 Fresenius SE & Co. KGaA 117
      • 10.4.1 Company Overview 117
      • 10.4.2 Financials 117
      • 10.4.3 Products 117
      • 10.4.4 Strategy 117
      • 10.4.5 Key Developments 117
    • 10.5 BD 118
      • 10.5.1 Company Overview 118
      • 10.5.2 Financials 118
      • 10.5.3 Products 118
      • 10.5.4 Strategy 118
      • 10.5.5 Key Developments 118
    • 10.6 GI Supply 119
      • 10.6.1 Company Overview 119
      • 10.6.2 Financials 119
      • 10.6.3 Products 119
      • 10.6.4 Strategy 119
      • 10.6.5 Key Developments 119
    • 10.7 Medtronic 120
      • 10.7.1 Company Overview 120
      • 10.7.2 Financials 120
      • 10.7.3 Products 120
      • 10.7.4 Strategy 120
      • 10.7.5 Key Developments 120

    11 Conclusion 121

    • 11.1 Key Findings 121
      • 11.1.1 From CEO’s View Point 121

    12 Appendix 122

    • 12.1 Discussion Blue Print 122

    Report You Might be Interested

    • USD
    • GBP
    • EURO
    • INR
    Credit card Logo

    Keywords